Episurf Medical AB (STO:EPISB), a provider of minimally invasive and personalised treatment alternatives for people with painful joint injuries, announced on Thursday the acquisition of SEK7m of financing within the agreement signed with European Select Growth Opportunities Fund (ESGO).
On 2 May 2018, Episurf Medical's board of directors had approved the first transaction with ESGO and granted the issue of a first tranche of convertible notes and warrants not applying the shareholders' pre-emption following the general shareholders' meeting 9 April 2018, where a new authorisation for the board of directors to issue notes and warrants was granted.
This issue relates to the agreement entered between Episurf and ESGO, announced on 23 February 2018.
In connection with the issue of the first tranche of 140 notes and 1,147,540 warrants to ESGO, Episurf has also issued 1,131,462 free warrants to its shareholders to protect them against dilution.
According to the company, in order to fulfil the requirements for the listing of the warrants on Nasdaq First North, Episurf and ESGO have entered on 2 May 2018 into an amendment agreement under which there shall be no warrants issued under the second tranche but instead the number of warrants issued under the first tranche shall be doubled.
The International Meeting of the European Society of Gynaecological Oncology (ESGO) at the ACC Liverpool this weekend is expected to bring PS5.7m to the city.
Dr John Green, senior lecturer at the University of Liverpool who is a consultant medical oncologist at Clatterbridge Cancer Centre and ESGO board member, worked with the Liverpool Bidding Partnership to bring the society's biennial conference to the waterfront venue.